Response within 8 days and durable response
Doptelet helps get patients to the ≥50 x 109/L target within days, and keeps them there for months*1,2
The efficacy and safety of Doptelet in adult patients with chronic ITP was evaluated in a Phase 3, multicentre, randomised, double-blind, parallel-group, placebo-controlled study.1
*Significantly more Doptelet patients achieved response by month 6 (87.5% vs. 5.9% placebo; P<0.0001).2
†Defined as a platelet count ≥50 x 109/L in the absence of rescue therapy.
‡Vs 0.0 with placebo (P<0.0001).1
Primary endpoint: Cumulative number of weeks of platelet response, defined as platelet count ≥50 x 109/L in the absence of rescue therapy over 6 months of once-daily treatment.1
*At EOT visit (visit 22), patients could enter the extension phase. Patients not continuing entered the dose-tapering and follow-up phase.1
†For patients who did not enter the extension phase.1
‡Optional entry into the open-label extension phase.1
§The screening visit and day 1 baseline/randomisation visit platelet counts were averaged to obtain the baseline platelet count value.1
IIPatients who discontinued early who met the criteria for a lack of treatment effect may have moved directly into the open-label extension phase.1
Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo aninvasive procedure. 3 Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). 3
ITP, immune thrombocytopenia; CONMED, concomitant medication; DOP, Doptelet; EOT, end-of-treatment; ITP, immune thrombocytopenia; qd, once daily; R, randomisation
References
1. Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183(3):479-490. 2. Al-Samkari H, Jiang D, Gernsheimer T, et al. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study. Br J Haematol. 2022;197(3):359-366. 3. Doptelet Summary of Product Characteristics. 22/05/2025